0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Immune Checkpoint Proteins > 4-1BB > 41B-H82E6

Biotinylated Human 4-1BB / TNFRSF9 Protein, His,Avitag™(MALS verified)

  • Synonym
    TNFRSF9,4-1BB,CD137,CDw137,ILA
  • Source
    Biotinylated Human 4-1BB, His,Avitag™(MALS verified) (41B-H82E6) is expressed from human 293 cells (HEK293). It contains AA Leu 24 - Gln 186 (Accession # Q07011-1).
    Predicted N-terminus: Leu 24
  • Molecular Characterization
    Online(Leu 24 - Gln 186) Q07011-1

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag.

    The protein has a calculated MW of 20.9 kDa. The protein migrates as 30-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Biotinylation
    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
  • Biotin:Protein Ratio
    The biotin to protein ratio is 0.5-1 as determined by the HABA assay.
  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >90% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Biotinylated Human 4-1BB, His,Avitag™(MALS verified) (Cat. No. 41B-H82E6) SDS-PAGE gel

Biotinylated Human 4-1BB, His,Avitag™(MALS verified) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

SEC-MALS
Biotinylated Human 4-1BB, His,Avitag™(MALS verified) (Cat. No. ) MALS images

The purity of Biotinylated Human 4-1BB, His,Avitag™(MALS verified) (Cat. No. 41B-H82E6) was more than 90% and around 25-35 kDa verified by SEC-MALS.

Bioactivity-ELISA
Biotinylated Human 4-1BB, His,Avitag™(MALS verified)Biotinylated Human 4-1BB, His,Avitag™(MALS verified) (Cat. No. 41B-H82E6) ELISA bioactivity

Immobilized Human 4-1BB Ligand (71-254), His,Flag Tag (active trimer) (MALS verified) (Cat. No. 41L-H52D4) at 1 μg/mL (100 μL/well) can bind Biotinylated Human 4-1BB, His,Avitag™(MALS verified) (Cat. No. 41B-H82E6) with a linear range of 1-39 ng/mL (QC tested).

Biotinylated Human 4-1BB, His,Avitag™(MALS verified)Biotinylated Human 4-1BB, His,Avitag™(MALS verified) (Cat. No. 41B-H82E6) ELISA bioactivity

Immobilized Biotinylated Human 4-1BB, His,Avitag™(MALS verified) (Cat. No. 41B-H82E6) at 1 μg/mL (100 μL/well) on Recombinant Streptavidin (Cat. No. STN-N5116) precoated (0.5μg/well) plate, can bind Human 4-1BB Ligand, Fc Tag (Cat. No. 41L-H5257) with a linear range of 0.1-2 ng/mL (Routinely tested).

  • Background
    4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.
  • References
    • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

    Comments (0)

    Order Details

    Price(USD) : $350.00

    Price(USD) : $1380.00

    Promotion & Exhibitions

    Drug Development Status

    • Number of Launched Drugs:0 Details
    • Number of Drugs in Clinical Trials:16 Details
    • Latest Research Phase:Phase ?

    Datasheet & Documentation

    Request for DMF
    DMF (Drug Master File)

    Contact Us

    +1  800-810-0816 (US)
    +86 400-682-2521 (AP)

    Questions & Comments

    This web search service is supported by Google Inc.

    totop